هدف از مطالعه حاضر، معرفی یک نرم افزار مدیریت الکترونیکی برای هزینه های بیماری (COL) و جمع آوری داده ها در افراد مبتلا به صرع در آلمان می باشد.
مواد و روش ها: اطلاعات در مورد وضعیت اجتماعی و اقتصادی هزینه های بیماری صرع با استفاده از یک پرسشنامه مبتنی بر این نرم افزار ثبت شده است.
یافته ها: در سال 2011، 359 نفر ثبت نام کردند که 170 نفر یعنی 47 درصد با سن بین 20 تا 50 در 6 شیوه بررسی شدند. اکثر بیماران برای بیش از یک سال (V=200) و در بیش از دو سوم، برای بهبود تشنج طولانی مدت بوده است. ((N=248) شامل 69 درصد) مجموع هزینه های سالانه، Є 1698 به ازای هر بیمار، با داروهای ضد تشنج 59 درصد کل هزینه های مستقیم و بیماران بستری در بیمارستان (3% درصد) به عنوان عوامل اصلی هزینه ها بوده است. از 252 بیمار ثبت نام شده 70 درصد در سن کار بودند که به علت بیماری E 745 در غیبت بودند.
تشخیص های اخیر نشان می دهد که عوامل رانندگی، یکی از علت های بالقوه در تشنج صرع می باشد. درمان تشنج در سن بالاتر از 65 سال با هزینه های دارویی پایین تر به دلیل تجویز داروهای ضد صرع قدیمی تر بوده است.
کلمات کلیدی: هزینه، بیماری صرع، هزینه های غیر مستقیم اقتصادی از دست دادن کار، استفاده از منابع.
Purpose: This study used an electronic practice management software in daily routine to gather long-
term disease and cost-of-illness (COI) data in patients with epilepsy in Germany.
Methods: Data on socio-economic status, course of epilepsy as well as direct and indirect costs were
recorded using practice software-based questionnaires.
Results: In 2011 we enrolled 359 patients (170 male (47.4%); mean age 50.5 20.7 years) in six neurological
practices. The majority of patients had been in long-term seizure remission for more than one year (n = 200,
55.7%) and in more than two-thirds the anti-epileptic drug (AED) monotherapy (n = 248, 69.1%) was used.
Levetiracetam (31%), lamotrigine (26%) and valproate (24%) were the drugs prescribed most frequently.
Total annual direct costs amounted to s1698 per patient with anticonvulsants (59.9% of total direct
costs) and hospitalization (30.0%) as the main cost factors. Of the patients enrolled 252 (70.2%) were of
working age and indirect annual costs due to absenteeism amounted to s745 per patient.
Potential cost-driving factors were seizure frequency and a recent diagnosis of epilepsy associated
with higher costs. Anticonvulsant treatment in patients aged 65 years and older was associated with
lower drug costs due to prescription of older AEDs.
Conclusion: We were able to demonstrate that electronic practice management software can easily be
used to perform long-term health economic evaluations with a bottom-up approach. The combination of
both physician- and patient-based electronic databases will facilitate performing less expensive studies,
but at the same time simplify large, prospective and multicentre clinical trials.
Purpose: This study used an electronic practice management software in daily routine to gather long-term disease and cost-of-illness (COI) data in patients with epilepsy in Germany.Methods: Data on socio-economic status, course of epilepsy as well as direct and indirect costs wererecorded using practice software-based questionnaires.Results: In 2011 we enrolled 359 patients (170 male (47.4%); mean age 50.5 20.7 years) in six neurologicalpractices. The majority of patients had been in long-term seizure remission for more than one year (n = 200,55.7%) and in more than two-thirds the anti-epileptic drug (AED) monotherapy (n = 248, 69.1%) was used.Levetiracetam (31%), lamotrigine (26%) and valproate (24%) were the drugs prescribed most frequently.Total annual direct costs amounted to s1698 per patient with anticonvulsants (59.9% of total directcosts) and hospitalization (30.0%) as the main cost factors. Of the patients enrolled 252 (70.2%) were ofworking age and indirect annual costs due to absenteeism amounted to s745 per patient.Potential cost-driving factors were seizure frequency and a recent diagnosis of epilepsy associatedwith higher costs. Anticonvulsant treatment in patients aged 65 years and older was associated withlower drug costs due to prescription of older AEDs.Conclusion: We were able to demonstrate that electronic practice management software can easily beused to perform long-term health economic evaluations with a bottom-up approach. The combination ofboth physician- and patient-based electronic databases will facilitate performing less expensive studies,but at the same time simplify large, prospective and multicentre clinical trials.
